Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709488 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
A Phase 1 study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Light Sciences Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 6
- Study locations
NCT00709488: Completed Phase 1 study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Light Sciences Oncology.
NCT00709488 is a Phase 1 study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms that has completed, run by Light Sciences Oncology. The registered enrollment target is 12 participants, below the 552-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00709488, a Phase 1 study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, has completed, sponsored by Light Sciences Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a phase 1 study to evaluate the safety and effectiveness of using the Litx™ BPH System in patients with LUTS due to benign prostatic hyperplasia (BPH).
Conditions Studied
Interventions
- DRUG Talaporfin sodium
- PROCEDURE Placement of device in prostate urethra
- DEVICE Transurethral illumination with light emitting diodes (Litx™ BPH Device)
Study Locations (6)
Washington
- Integrity Medical Research - Mountlake Terrace
- Seattle Urological Associates - Seattle
Alaska
- Alaska Clinical Research Center - Anchorage
California
- UCLA School of Medicine, GU Clinical Trials Office - Los Angeles
Oregon
- The Portland Clinic - Portland
Texas
- Urology San Antonio Research - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
What the finished NCT00709488 record still lists
NCT00709488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 552-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 3 interventions - of which Talaporfin sodium is the first listed.
NCT00709488 lists 6 locations in 5 states (Washington, Alaska, California).
Frequently Asked Questions
What is clinical trial NCT00709488 about?
NCT00709488 is a clinical study titled "Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)". This is a phase 1 study to evaluate the safety and effectiveness of using the Litx™ BPH System in patients with LUTS due to benign prostatic hyperplasia (BPH).
What is the current status of trial NCT00709488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-06. Estimated completion is 2011-04.
What conditions does trial NCT00709488 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms.
What interventions are being tested in trial NCT00709488?
The interventions under investigation include: Talaporfin sodium (DRUG), Placement of device in prostate urethra (PROCEDURE), Transurethral illumination with light emitting diodes (Litx™ BPH Device) (DEVICE).
Who is sponsoring clinical trial NCT00709488?
This trial is sponsored by Light Sciences Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00709488 being conducted?
This trial has 6 study locations across Alaska, California, Oregon, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00709488's enrollment target sits among peer trials
12 30th of 29 the lowest of 29 other Benign Prostatic Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
COMPLETED · Phase 1
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
RECRUITING
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia